Wolfe Research Affirms Outperform Rating on Johnson & Johnson (JNJ) on Improving Fundamentals

In This Article: Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs’ top healthcare stock picks. On July 10, analysts at Wolfe Research reiterated an ‘Outperform’ rating on the stock and a $175 price target. The bullish stance underscores the company’s strong performance year to date amid…